'Our objective is to select one of several lead compounds for IND-enabling studies by December of this year,” said Sofia...'

https://www.bizjournals.com/philadelphia/news/2019/10/10/arbutus-biopharma-halts-study-hepatitis-b-cure.html?ana=yahoo&yptr=yahoo

After almost killing 2 healthy volunteers and producing failure after failure, I had hope that he will be so gracious to step down on his own. But instead he is now promising the umpteenth time that next time will be different. Let's entertain his idea for a moment: from start of IND-enabling study to IND, IND acceptance and actual study start: mid-2021. Results from that trial in early 2022; combo study start in late 2023.

Only a 2 1/2 year delay... Please BoD, get rid of this person.

On a positive note, it seems that the stock has bottomed. Selling has dried out entirely. When I put in a buy order for 70k shares at ask, I've been getting a handful of shares the last 2 days and the stock ends up.